Aerovate Therapeutics, Inc. (AVTE)

NASDAQ: AVTE · Delayed Price · USD
8.25
-0.43 (-4.95%)
At close: Jan 21, 2022 4:00 PM
8.13
-0.12 (-1.45%)
After-hours:Jan 21, 2022 4:07 PM EST
Market Cap201.39M
Revenue (ttm)n/a
Net Income (ttm)-18.41M
Shares Out24.41M
EPS (ttm)-2.97
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume42,676
Open8.42
Previous Close8.68
Day's Range7.74 - 9.26
52-Week Range8.00 - 29.43
Betan/a
AnalystsStrong Buy
Price Target24.67 (+199.0%)
Earnings Daten/a

About AVTE

Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

IndustryBiotechnology
IPO DateJun 30, 2021
Employees8
Stock ExchangeNASDAQ
Ticker SymbolAVTE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for AVTE stock is "Strong Buy." The 12-month stock price forecast is 24.67, which is an increase of 199.03% from the latest price.

Price Target
$24.67
(199.03% upside)
Analyst Consensus: Strong Buy

News

Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hyperten...

WALTHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives o...

1 month ago - GlobeNewsWire

Aerovate Therapeutics Announces Third Quarter 2021 Financial Results

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives o...

2 months ago - GlobeNewsWire

Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index

WALTHAM, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives ...

4 months ago - GlobeNewsWire

Aerovate Therapeutics Announces Second Quarter 2021 Financial Results

WALTHAM, Mass. , Aug. 16, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc.   (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the live...

5 months ago - GlobeNewsWire

Aerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option ...

BOSTON, July 02, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patien...

6 months ago - GlobeNewsWire

Drug Formulation Developer Aerovate Therapeutics Kick Starts Trading Today With Upsized Debut

Just shy of a full year after emerging from stealth mode, Aerovate Therapeutics Inc (NASDAQ: AVTE) is listing onto NASDAQ with an upsized offering. The company priced 8.68 million shares at $14, the mid...

6 months ago - Benzinga

Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON, June 29, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patien...

6 months ago - GlobeNewsWire